These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11142437)

  • 1. Risperidone in treating behavioural disturbances of Prader-Willi syndrome.
    Durst R; Rubin-Jabotinsky K; Raskin S; Katz G; Zislin J
    Acta Psychiatr Scand; 2000 Dec; 102(6):461-5. PubMed ID: 11142437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome.
    Araki S; Ohji T; Shiota N; Dobashi K; Shimono M; Shirahata A
    Pediatr Int; 2010 Feb; 52(1):e1-3. PubMed ID: 20158635
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catatonia in an adolescent with Prader-Willi Syndrome.
    Dhossche DM; Bouman NH
    Ann Clin Psychiatry; 1997 Dec; 9(4):247-53. PubMed ID: 9511949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome.
    Banga A; Connor DF
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):396-8. PubMed ID: 23083028
    [No Abstract]   [Full Text] [Related]  

  • 7. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between antipsychotics and weight in patients with Prader-Willi syndrome.
    Elliott JP; Cherpes G; Kamal K; Chopra I; Harrison C; Riedy M; Herk B; McCrossin M; Kalarchian M
    Pharmacotherapy; 2015 Mar; 35(3):260-8. PubMed ID: 25809177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label trial of risperidone in children and adolescents with severe mood dysregulation.
    Krieger FV; Pheula GF; Coelho R; Zeni T; Tramontina S; Zeni CP; Rohde LA
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):237-43. PubMed ID: 21663426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone in Prader-Willi syndrome.
    Durst R; Rubin-Jabotinsky K; Raskin S; Katz G; Zislin J
    J Am Acad Child Adolesc Psychiatry; 2000 May; 39(5):545-6. PubMed ID: 10802969
    [No Abstract]   [Full Text] [Related]  

  • 12. Risperidone in children with autism and serious behavioral problems.
    McCracken JT; McGough J; Shah B; Cronin P; Hong D; Aman MG; Arnold LE; Lindsay R; Nash P; Hollway J; McDougle CJ; Posey D; Swiezy N; Kohn A; Scahill L; Martin A; Koenig K; Volkmar F; Carroll D; Lancor A; Tierney E; Ghuman J; Gonzalez NM; Grados M; Vitiello B; Ritz L; Davies M; Robinson J; McMahon D;
    N Engl J Med; 2002 Aug; 347(5):314-21. PubMed ID: 12151468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
    Kurz A; Delius-Stute H; Rettig K; Schwalen S
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():89-95. PubMed ID: 15490773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
    Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
    Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
    Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M
    Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.